A growing number of Chinese companies specializing in brain-computer interface (BCI) technology are preparing for initial public offerings (IPOs) on domestic exchanges. These firms are increasingly targeting the Shanghai Stock Exchange’s Star Market, a venue often compared to the U.S. Nasdaq that focuses on high-tech and innovative enterprises.

This shift is largely driven by a surge in private capital investment, which has identified the BCI sector as a high-growth area. Arfysica Innovation, a company based in Shanghai, is the most recent firm to register for IPO coaching, a mandatory preliminary step for companies planning to list on the Star Market. The move by these BCI firms aligns with a broader trend of Chinese technology companies seeking domestic listings to capitalize on local investor enthusiasm for advanced hardware and medical technology. While the sector is currently viewed as a "darling" of private equity, the transition to public markets marks a significant step in the commercialization of neurotechnology within China.